



PHONE: 605-773-3495 | FAX: 605-773-5246

WEB: [DSS Medicaid Prior Authorizations](#) | EMAIL : [DSSMedicaidpa@state.sd.us](mailto:DSSMedicaidpa@state.sd.us)

## ECULIZUMAB PRIOR AUTHORIZATION REQUEST FORM

Use this form when therapy is requested for neuromyelitis optica spectrum disorder (NMOSD)

This form **MUST BE** submitted with medical records to support services

Date:		
<b>RECEIPIENT INFORMATION</b>		
Medicaid ID:	Date of Birth:	Sex:    M        F
Last Name:		First Name:
<b>GENERAL INFORMATION</b>		
First Date of Service:		Last Date of Service:
Primary Diagnosis Code:		HCPC Code:
Drug Name:		Dose & Frequency:
Hospitalizations/Treatments/Medications Used in the last 6 months:		
<b>POINT OF CONTACT</b>		
Name and Title:		
Email:	Phone:	Fax:
<i>Note: The point of contact is the individual completing the PA and would be the contact for questions SD Medicaid may have regarding the PA. The determination notice will be sent to the listed point of contact.</i>		
<b>REFERRING PROVIDER INFORMATION</b>		
Name:		
NPI #:		Taxonomy:
Phone:		Fax:
<b>SERVICING PROVIDER INFORMATION</b>		
Name:		
Address:		
NPI #:		Taxonomy:
Phone:		Fax:

<b>CRITERIA</b>		
<b>Medical records to support use of product are submitted</b>		
<b>Initial Therapy (check one)</b>	<b>Yes</b>	<b>No</b>
	Requested therapy is for Soliris only	
	Therapy is requested by or in consultation with a neurologist	
	Individual is ≥18 years of age	
	Individual has a documented diagnosis of NMOSD with presence of seropositive aquaporin-4 (AQP4) antibodies	
	Individual has symptoms consistent with at least <b>one</b> core clinical characteristic below: <ul style="list-style-type: none"> <li>• Optic neuritis</li> <li>• Acute myelitis</li> <li>• Area postrema syndrome or episode of otherwise unexplained hiccups or nausea and vomiting</li> <li>• Acute brainstem syndrome</li> <li>• Symptomatic narcolepsy</li> <li>• Acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions</li> <li>• Symptomatic cerebral syndrome with NMOSD-typical brain lesions</li> </ul>	
	Documentation is provided indicating previous failure, contraindication, or intolerance to <b>at least two</b> of the following therapies (with at least one of them being a C5 complement inhibitor): <ul style="list-style-type: none"> <li>• Rituximab</li> <li>• Tocilizumab</li> <li>• Inebilizumab (Uplizna)</li> <li>• Satralizumab-mwge (Enspryng)</li> <li>• Ravulizumab (Ultomiris)</li> </ul>	
	Documentation is provided indicating at least 2 relapses in last 12 months or 3 relapses in the last 24 months with at least 1 relapse in the last 12 months	
	Therapy is not being used in combination with other biologics for NMOSD (e.g. inebilizumab, rituximab, satralizumab, tocilizumab, etc.)	
	Individual has an Expanded Disability Status Score (EDSS) score documented at baseline	
<b>Continuation of Therapy (check one)</b>	<b>Yes</b>	<b>No</b>
	Therapy is not prescribed in combination with other biologics for the requested indication	
	Individual has had a positive clinical response with reduction in number and/or severity of relapses or signs and symptoms of NMOSD	
	Documentation is provided indicating recent (within 2 months) EDSS	
<b>PHYSICIAN SIGNATURE – PROVIDER ONLY</b>		
This form <u>must be</u> signed by a provider		
	I certify that the information given in this form is a true and accurate medical indication for the required product	
<b>Name &amp; Title (Printed):</b>		<b>Specialty:</b>
<b>Signature:</b>		